Literature DB >> 18566443

Contribution of antibody and T cell-specific responses to the progression of 139A-scrapie in C57BL/6 mice immunized with prion protein peptides.

Antoine Sacquin1, Anne Sophie Bergot, Pierre Aucouturier, Martine Bruley-Rosset.   

Abstract

Prion diseases are associated with the conversion of the normal host cellular prion protein to an abnormal protease-resistant (PrPres) associated with infectivity. No specific immune response against prions develops during infection due to the strong tolerance to cellular prion protein. We examined the protective potential on prion diseases of immune responses elicited in C57BL/6 mice with PrP peptides 98-127 (P5) or 158-187 (P9) with CpG. After immunization, P5-treated mice developed high titer and long-lasting Abs, and P9-treated mice developed transient IFN-gamma secreting T cells and poor and variable Ab responses. Both treatments impaired early accumulation of PrPres in the spleen and prolonged survival of mice infected with 139A scrapie. Additional P9 boosts after 139A infection sustained the T cell response and partially inhibited PrPres early accumulation but did not improve the survival. Surprisingly, when P9 injections were started 1 mo after infection and repeated subsequently, specific T cell and Ab responses were impaired and no beneficial effect on prion disease was observed. After a single injection of P9, the number of IFN-gamma secreting CD4+ T cells was also reduced in mice 8- to 10-wk postinfection compared with healthy mice. In vivo and in vitro removal of CD4+CD25+ T cells restored the T cell response to P9 in infected mice. In conclusion, CD4+ T cells as well as Abs might participate to the protection against scrapie. Of importance, the peripheral accumulation of PrPres during infection negatively interferes with the development of T and B cell responses to PrP and regulatory T cells might contribute to this phenomenon.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566443     DOI: 10.4049/jimmunol.181.1.768

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy.

Authors:  Qiao Li; Seagal Teitz-Tennenbaum; Elizabeth J Donald; Mu Li; Alfred E Chang
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

Review 2.  The immunobiology of prion diseases.

Authors:  Adriano Aguzzi; Mario Nuvolone; Caihong Zhu
Journal:  Nat Rev Immunol       Date:  2013-11-05       Impact factor: 53.106

3.  Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie.

Authors:  Saci Iken; Véronique Bachy; Pauline Gourdain; Annick Lim; Sylvie Grégoire; Thomas Chaigneau; Pierre Aucouturier; Claude Carnaud
Journal:  PLoS Pathog       Date:  2011-09-01       Impact factor: 6.823

4.  Exacerbation of experimental autoimmune encephalomyelitis in prion protein (PrPc)-null mice: evidence for a critical role of the central nervous system.

Authors:  Pauline Gourdain; Clara Ballerini; Arnaud B Nicot; Claude Carnaud
Journal:  J Neuroinflammation       Date:  2012-01-26       Impact factor: 8.322

5.  Dendritic cell-mediated-immunization with xenogenic PrP and adenoviral vectors breaks tolerance and prolongs mice survival against experimental scrapie.

Authors:  Martine Bruley Rosset; Antoine Sacquin; Sylvie Lecollinet; Thomas Chaigneau; Micheline Adam; François Crespeau; Marc Eloit
Journal:  PLoS One       Date:  2009-03-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.